Greenwich Lifesciences Inc (GLSI) is trading down at $15.48 (-6.58%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Operating income | −$3.43M | −$1.86M | −$4.60M | −$8.04M | −$9.33M | −$17.6M | −$19.4M |
| Net income | −$3.43M | −$1.86M | −$4.57M | −$7.83M | −$8.89M | −$17.4M | −$19.4M |
| EPS (diluted) | −$1.52 | −$0.20 | −$0.35 | −$0.61 | −$0.69 | −$1.34 | −$1.43 |
| Balance sheet | |||||||
| Cash and equivalents | $6.83K | $28.7M | $27.2M | $13.5M | $6.99M | $4.09M | $6.18M |
| Total assets | $26.7K | $28.7M | $27.2M | $13.5M | $6.99M | $4.09M | $6.18M |
| Total liabilities | $1.38M | $1.05M | $385.2K | $262.9K | $294.4K | $3.19M | $5.82M |
| Shareholders' equity | −$1.35M | $27.6M | $26.8M | $13.2M | $6.70M | $908.6K | $353.2K |
| Cash flow | |||||||
| Operating cash flow | −$293.3K | −$1.15M | −$4.29M | −$6.20M | −$6.48M | −$7.27M | −$9.91M |
| Share buybacks | — | — | — | $7.54M | — | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$2.73M | −$9.71M | −$2.77M | −$3.77M | −$4.17M | −$8.74M | −$5.73M | −$4.02M |
| Net income | −$2.67M | −$9.67M | −$2.74M | −$3.75M | −$3.71M | −$9.15M | −$5.66M | −$3.95M |
| EPS (diluted) | −$0.20 | −$0.75 | −$0.21 | −$0.28 | −$0.27 | −$0.67 | −$0.39 | −$0.27 |
| Balance sheet | ||||||||
| Cash and equivalents | $5.82M | $4.09M | $2.75M | $3.13M | $3.81M | $6.18M | $10.5M | $8.88M |
| Total assets | $5.83M | $4.09M | $2.75M | $3.13M | $3.81M | $6.18M | $10.5M | $8.88M |
| Total liabilities | $842.4K | $3.19M | $2.55M | $2.52M | $2.02M | $5.82M | $5.24M | $5.76M |
| Shareholders' equity | $4.98M | $908.6K | $200.5K | $604.3K | $2.18M | $353.2K | $5.27M | $3.12M |
| Cash flow | ||||||||
| Operating cash flow | −$2.58M | −$1.85M | −$1.83M | −$2.23M | −$2.67M | −$3.17M | −$4.70M | −$1.94M |
From Greenwich Lifesciences Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Greenwich Lifesciences Inc in our feed yet.